Retatrutide Phase 3 (TRANSCEND‑T2D‑1) cut A1C up to 2.0% and body weight up to 16.8% after 40 weeks
Eli Lilly’s investigational triple agonist retatrutide produced large reductions in both A1C and body weight in TRANSCEND‑T2D‑1, a 537‑person Phase…
Eli Lilly’s investigational triple agonist retatrutide produced large reductions in both A1C and body weight in TRANSCEND‑T2D‑1, a 537‑person Phase…